Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 18, 2019updated 23 Dec 2019 10:22am

Paragon launches new firm with focus on AI diagnostics

Life science innovator Paragon Biosciences has launched Qlarity Imaging, a new company which will focus on leveraging artificial intelligence (AI) technology to boost medical outcomes and lower costs.

Life science innovator Paragon Biosciences has launched Qlarity Imaging, a new company which will focus on leveraging artificial intelligence (AI) technology to boost medical outcomes and lower costs.

The new firm will advance QuantX, the first-ever FDA-cleared computer-aided breast cancer diagnosis system in radiology. The solution features intuitive displays, advanced analytics and machine learning.

In a clinical study, QuantX is said to have demonstrated effectiveness in helping radiologists interpret cancerous and non-cancerous breast lesions.

The AI solution showed a 39% decrease in missed breast cancers without a reduction in specificity, and a 20% overall diagnostic improvement.

Qlarity Imaging intends to further expand the AI technology’s diagnostic applications to other image modalities and medical conditions.

Paragon Biosciences chairman and CEO Jeff Aronin said: “By driving innovation across life sciences, Paragon fulfils its mission of improving outcomes for patients with severe medical conditions. So, we’re pleased to help further develop the first FDA-cleared, AI-enabled diagnostic software for breast cancer MRIs.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

“We are entering an exciting time where advances in supercomputing and machine learning make it possible for AI to deliver on its promise for drug discovery, drug development, and diagnostics.”

Qlarity Imaging will leverage Paragon’s capabilities and investment to support further development and deployment of its computer-aided diagnosis system and expand AI diagnostic tools.

In addition, Paragon offers guidance on using AI to improve the diagnostic insight of medical devices, speed of drug development and enhance treatment efficacy.

Qlarity Imaging advisor Dr Maryellen Giger said: “Paragon is already delivering on its promise, helping Qlarity Imaging to expand its management team, pursue new product opportunities, extend its customer base, and seek additional venture financing.”

Qlarity’s AI image processing and diagnostic algorithms are based on Giger’s research, noted Paragon.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU